17:35 , Nov 4, 2016 |  BC Week In Review  |  Company News

Kolltan, Celldex deal

Celldex will acquire cancer company Kolltan for 19.2 million Celldex shares valued at $60.5 million based on the company's close of $3.15 on Oct. 31, the day before the deal was announced. Kolltan shareholders are...
23:22 , Nov 1, 2016 |  BC Extra  |  Company News

Celldex acquiring Kolltan

Celldex Therapeutics Inc. (NASDAQ:CLDX) will acquire cancer company Kolltan Pharmaceuticals Inc. (New Haven, Conn.) in a stock deal, including shares valued at $62.5 million up front. Kolltan shareholders are also eligible for $172.5 million in...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Kolltan preclinical data

In 12 evaluable dogs with spontaneous mast cell tumors, KTN0158 led to 5 partial responses and 7 cases of stable disease. The most common adverse events reported were anemia, neutropenia and thrombocytopenia. Data were presented...